C4X Discovery expands collaboration with Evotec on small-molecule drugs

28 September 2016

UK-based C4X Discovery (AIM: C4XD) and German biotech Evotec (EVT: Xetra) have announced a collaboration to develop new small-molecule drugs across a range of targets, therapeutic areas and stages of development, with initial programs focusing on cancer and autoimmune diseases.

The new agreement, financial terms of which have not been disclosed, builds on the strategic collaboration between the two companies announced in January 2015.

This new, longer-term strategic alliance will be a risk-shared multi-target program with a minimum of three projects active at any point in time.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK